CandlesenseCandlesense
News/Companies/ICCC

ICCC News

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025

ICCC

PORTLAND, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2025.

August 14, 2025Earnings
Read more →

ImmuCell Announces Bank Debt Refinancing

ICCC

PORTLAND, Maine, Aug. 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced it has successfully refinanced a portion of its bank debt.

August 12, 2025Finance
Read more →

ImmuCell Q1 EPS $0.16 Up From $(0.06) YoY, Sales $8.07M Up From $7.26M YoY

ICCC

May 14, 2025
Read more →

ImmuCell Preliminary Q1 2025 Revenue Of $8.1M Up From $7.3M YoY; Reduced The Backlog Of Orders To $4M As Of March 31, 2025, From $4.4M As Of December 31, 2024

ICCC

April 8, 2025
Read more →

ImmuCell Initiates Investigational Product Use Of Re-Tain

ICCC

April 2, 2025
Read more →

ImmuCell Q4 EPS $0.06 Up From $(0.15) YoY, Sales $7.75M Up From $5.10M YoY

ICCC

February 25, 2025
Read more →

Reported Earlier, ImmuCell Preliminary Q4 Sales Of $7.8M (+52% YoY) and Fiscal 2024 Of $26.5M (+52% YoY), Driven by Increased Production

ICCC

January 10, 2025
Read more →